Zom­bie biotech Eleven Bio sheds staff in the fi­nal wind down

Ham­mered by back-to-back piv­otal tri­al fail­ures, Eleven Bio­ther­a­peu­tics ($EBIO) is con­tin­u­ing to wind down its op­er­a­tions. The biotech not­ed that it whacked 14 staffers last week, ac­cord­ing to a no­tice filed with the SEC on Wednes­day.

By its own ac­count, there’s a skele­ton staff of 4 still in place, with less and less on the ta­ble. The oph­thal­mol­o­gy-fo­cused com­pa­ny did not re­spond to a re­quest for com­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.